Workflow
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates
ACLXArcellx(ACLX) ZACKS·2025-05-08 22:10

Company Performance - Arcellx, Inc. reported a quarterly loss of 1.13pershare,whichwasworsethantheZacksConsensusEstimateofalossof1.13 per share, which was worse than the Zacks Consensus Estimate of a loss of 0.84, and compared to a loss of 0.14pershareayearago,indicatingasignificantdeclineinperformance[1]−Thecompanypostedrevenuesof0.14 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of 8.13 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 55.30%, and a decrease from year-ago revenues of 39.26million[2]−Overthelastfourquarters,ArcellxhassurpassedconsensusEPSestimatesonlytwotimesandhasnotbeatenconsensusrevenueestimatesduringthisperiod[2]StockMovementandOutlook−Arcellxshareshavedeclinedapproximately3139.26 million [2] - Over the last four quarters, Arcellx has surpassed consensus EPS estimates only two times and has not beaten consensus revenue estimates during this period [2] Stock Movement and Outlook - Arcellx shares have declined approximately 31% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is -0.89 on revenues of 17.86million,andforthecurrentfiscalyear,itis−17.86 million, and for the current fiscal year, it is -3.27 on revenues of $84.82 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Arcellx belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Arcellx's stock performance [5][6]